The first time you really notice your meniscus is usually the moment a surgeon tells you part of it has to come out. The crescent of cartilage that cushions the knee does not regenerate well, and once it tears badly enough, the standard fix in an American operating room is to trim away the damaged tissue and send the patient home with a thinner shock absorber and a higher lifetime risk of osteoarthritis. OrthoPreserve, a five-year-old company headquartered in Atlanta, wants to put a synthetic replacement on that surgeon's tray instead.
The company is developing a meniscus implant that, in early 2025, received both FDA Breakthrough Device Designation and enrollment in the agency's Total Product Life Cycle Advisory Program (TAP), a relatively small pilot intended to compress the regulatory and reimbursement runway for high-impact devices [PR Newswire]. Those two designations together are the kind of signal that gets noticed inside orthopedic strategy departments. Breakthrough status alone is competitive; pairing it with TAP enrollment is rarer, and it suggests FDA reviewers see the meniscus gap as a meaningful unmet need rather than an incremental upgrade to existing repair kits.
The bet
OrthoPreserve's wager is that the current standard of care leaves an enormous middle category of patients underserved. On one end of the spectrum, surgeons can attempt to suture a torn meniscus back together, which works best for younger patients with clean tears in well-vascularized tissue. On the other end, for end-stage joint damage, there is total knee replacement. In between sits the partial meniscectomy: fast, cheap, and associated with accelerated cartilage wear over the following decade. An off-the-shelf implant that restores the load-bearing geometry of the meniscus would, in theory, slot directly into that middle, giving orthopedic surgeons a third option they do not currently have in any FDA-approved form in the United States.
The technology was developed at Georgia Tech and spun out into a company in 2021, with founder Jonathan Schwartz carrying the work from a graduate research project into a venture-backed startup [Georgia Tech, July 2024]. Schwartz has discussed the path from academic thesis to medical device company in interviews with the Atlanta startup press, framing the implant as a way to preserve native joint mechanics rather than replace them [Hypepotamus].
Why it could be big
The meniscus replacement category has been a graveyard for ambitious devices and also, increasingly, a magnet for them. The competitive set listed for OrthoPreserve includes Active Implants, whose NUsurface device has been pursuing US approval for years, the UK-based Orteq Ltd, and Stryker, the orthopedic giant that would be the most obvious acquirer if any of these implants reach commercial scale. The presence of a strategic like Stryker in the comparable set matters: it signals both that the market is large enough to attract a top-three orthopedic OEM and that an exit path exists if a startup can clear the clinical bar that larger competitors have struggled with.
Early non-dilutive support has come from the National Institutes of Health in the form of an SBIR grant, with additional backing from Activation Capital, a Richmond-based life sciences investor, and accelerator support from ATDC, the Georgia Tech-affiliated technology incubator that has produced a long list of Atlanta-area medtech graduates. For a pre-clinical device company, that mix (federal grant dollars, a regional life sciences investor, and a university-tied accelerator) is a fairly standard early capital stack, and it tends to bridge a company to the larger Series A rounds that orthopedic implants typically need to fund first-in-human studies.
| Milestone | Status | Source |
|---|---|---|
| Company founded | 2021 | Georgia Tech |
| NIH SBIR grant | Awarded | Structured facts |
| FDA Breakthrough Device Designation | Granted (early 2025) | PR Newswire |
| FDA TAP enrollment | Granted (early 2025) | PR Newswire |
| Clinical stage | Pre-clinical | Georgia Tech |
The team and traction
Schwartz, the founder, brought the implant out of Georgia Tech and has been the public face of the company through its early funding and regulatory milestones [Georgia Tech, July 2024]. The company has presented at the Southeast Venture Showcase, a regional forum that tends to attract life sciences generalists and strategic scouts, and has used the FDA designations as the centerpiece of its outbound communications in 2025 [Southeast Venture Showcase; PR Newswire]. For a pre-clinical device, the traction story is necessarily about regulatory posture and capital formation rather than revenue, and on those two axes the company has moved further in the past twelve months than most peers at the same stage.
The honest counterfactual
What bears will say is straightforward: meniscus implants have a difficult clinical history, and Active Implants in particular has spent more than a decade and multiple clinical trials pursuing US approval for NUsurface without yet crossing the finish line. The path from Breakthrough Designation to a pivotal trial readout is long, expensive, and littered with devices that performed well in the lab and disappointed in patients. What bulls answer is that OrthoPreserve is entering the category with the benefit of a decade of published clinical learning from those predecessors, the regulatory tailwind of TAP enrollment (which is explicitly designed to compress timelines for devices like this), and a strategic landscape in which a successful Phase 1 readout would attract serious attention from the major orthopedic OEMs named among its competitors.
What to watch
The next twelve months are likely to be defined by two things: a priced equity round to fund first-in-human work, and the design-freeze and IDE submission process that turns a pre-clinical device into a clinical-stage one. Watch for a Series A announcement, watch for any disclosed surgeon-investigator relationships at academic orthopedic centers, and watch the cadence of TAP-related communications with FDA, which is the most concrete signal that the agency's accelerated pathway is actually shortening the runway. If those pieces arrive on schedule, OrthoPreserve will be one of a very small number of US companies positioned to answer a question the orthopedic field has been circling for twenty years: what do you give the patient whose meniscus is too damaged to repair and whose knee is too healthy to replace?